HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Thematic (Sector/Industry)

<ul>
<li>The successful approval of Legend Biotech's CAR-T therapy indicates the FDA is objective. But we can judge FDA's attitude and globalization logic more clearly through Junshi’s PD-1 result in April.</li>
<li>Let's talk about the cyclical nature of innovative drugs. Humans, they repeat history all the time.</li>
<li>The current pet vaccine market in China is in the blue ocean, with a huge space for growth. This market has become an investment option that cannot be ignored.</li>
</ul>


The successful approval of Legend Biotech's CAR-T therapy indicates the FDA is objective. But we can judge FDA's attitude and globalization logic more clearly through Junshi’s PD-1 result in April.
Let's talk about the cyclical nature of innovative drugs. Humans, they repeat history all the time.
The current pet vaccine market in China is in the blue ocean, with a huge space for growth. This market has become an investment option that cannot be ignored.


China Healthcare Weekly (Mar.4)-Innovative Drug Cyclical Nature, Pet Vaccine Mkt, Legend Bio, Junshi

<p>China's pet care industry emerged in the 1990s. The gradual lifting of the pet keeping ban and the introduction of western pet brands started the development of China’s pet care industry. After the 21st century, the number of pets in China has grown rapidly. Pets have not only entered people's daily life, but also enlightened the pet economy and opened the development of related industries. For example, the China pet care market has gradually formed an industrial chain from the upstream products to the downstream services. The pet medical industry is the second largest core industry after pet food industry. The following mainly analyzed the China pet medical industry in terms of market potential, industry chain, pet hospital, and other investment opportunities.</p>

China's pet care industry emerged in the 1990s. The gradual lifting of the pet keeping ban and the introduction of western pet brands started the development of China’s pet care industry. After the 21st century, the number of pets in China has grown rapidly. Pets have not only entered people's daily life, but also enlightened the pet economy and opened the development of related industries. For example, the China pet care market has gradually formed an industrial chain from the upstream products to the downstream services. The pet medical industry is the second largest core industry after pet food industry. The following mainly analyzed the China pet medical industry in terms of market potential, industry chain, pet hospital, and other investment opportunities.

Industry Report - Insights on China Pet Medical Industry

China

Tianjin Ringpu Bio-Technology Company Limited researches, develops, manufactures and sells veterinary chemical pharmaceutical preparations and bio-pharmaceutical preparations.

Tianjin Ringpu Bio Technology Co,Ltd. (300119 CH)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Tianjin Ringpu Bio Technology Co,Ltd. (300119 CH)

China Healthcare Weekly (Mar.4)-Innovative Drug Cyclical Nature, Pet Vaccine Mkt, Legend Bio, Junshi

Junshi’s PD-1 result in April is more representative to judge FDA's attitude and globalization logic. We probably are at the tail end of mab drug...

Xinyao (Criss) Wang

Industry Report - Insights on China Pet Medical Industry

This article analyzed China pet medical industry in terms of market potential, industry chain, pet hospital (such as New Ruipeng Pet Healthcare...

Xinyao (Criss) Wang

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)